Evaluation of the Role of miR-1 in the Pathogenesis and as a Biomarker in Muscular Dystrophies and Congenital Myopathies
This study aims to understand if a special molecule in the blood, called miR-1, can act like a warning sign or a way to track the health of people with certain muscle conditions. We know that miR-1 helps our muscle cells grow and stay healthy, and its levels can be different in people with muscle-wasting diseases. Researchers want to compare miR-1 levels in the blood of four groups: people with Duchenne or Becker muscular dystrophy, those with Myotonic Dystrophy Type 1, individuals with congenital myopathies, and healthy volunteers. By doing this, they hope to discover if miR-1 levels can accurately show how a muscle condition is changing over time.
At a glance
What is this study about?
This study is looking into whether a tiny messenger molecule, called miR-1, found in your blood, can help doctors better understand and track certain muscle diseases. Think of miR-1 as a tiny switch that helps control how your muscle and heart cells grow and stay healthy. In some muscle-wasting conditions, the levels of this tiny messenger can be different from normal. We want to see if these differences can tell us more about how a person’s muscle disease is progressing.
The main idea is to compare the amounts of miR-1 in the blood across different groups of people. This includes those with Duchenne muscular dystrophy, Becker muscular dystrophy, Myotonic Dystrophy Type 1 (sometimes called Steinert's disease), and other muscle conditions present from birth (congenital myopathies). We'll also compare these levels to those in healthy people who don't have these conditions. By doing this, we hope to learn if miR-1 levels can serve as a useful indicator for how these muscle diseases are developing and changing over time, potentially helping doctors to monitor patients more effectively.
Ultimately, this research could lead to new ways of tracking these conditions without needing more invasive tests. If miR-1 proves to be a reliable marker, it could help doctors make more informed decisions about treatment and care, and give a clearer picture of how well a person is managing their condition. It's about finding simpler ways to keep an eye on these complex muscle diseases.
Key takeaways
- This study investigates if a blood molecule (miR-1) can track muscle disease progression.
- It aims to simplify monitoring for conditions like Duchenne and Myotonic Dystrophy.
- Participation mainly involves providing a single blood sample.
- Healthy volunteers are also needed for comparison.
- Findings could lead to better ways to understand and manage muscle diseases.
Who may be eligible?
To join this study, people need to be at least 2 years old. If you're a child, your parents or guardians would need to agree to your participation. Everyone taking part, or their guardians, must understand and freely agree to be part of the research.
You would be able to participate if you have Duchenne muscular dystrophy, Becker muscular dystrophy, Myotonic Dystrophy Type 1, or a congenital myopathy. Healthy volunteers are also needed for comparison. You'll also need to be part of the French social security system.
However, some things would prevent you from taking part. You can't join if you, or your parents/guardians, don't want to. If you've recently done very intense exercise within 10 days of a blood test, or are taking medicines that might affect the study results, you wouldn't be able to participate. Pregnant or breastfeeding women, people who are legally restricted, or those with another health problem that might affect the study results, also cannot join.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you, or the participant, at least 2 years old?
- Do you have Duchenne/Becker Muscular Dystrophy, Myotonic Dystrophy Type 1, or a congenital myopathy, or are you a healthy volunteer?
- Are you part of the French social security system?
- Have you avoided intense exercise in the last 10 days before a potential blood test?
- Are you pregnant or breastfeeding (if applicable) – if so, you cannot participate.
What does participation involve?
This study doesn't involve taking new medications or having any special treatments. Your participation would mainly involve giving a blood sample. The researchers will then measure the levels of miR-1 in your blood. You might also have some information collected about your age and the specific symptoms or severity of your muscle condition, if you have one. There are no follow-up visits or long-term commitments for this study, as it primarily involves a single blood draw to collect the necessary data.
Potential risks and benefits
Locations (1)
- CHU de Clermont-FerrandVerified postcodeClermont-Ferrand, France· Recruiting
Common questions
What is miR-1?
miR-1 is a tiny molecule found in your blood that helps control how your muscle and heart cells grow and stay healthy.
Why is this study important?
It could help find a simpler way to track muscle diseases like muscular dystrophy using a blood test, which might mean fewer invasive tests in the future.
Do I have to take any new medicine?
No, this study does not involve taking any new medications or treatments. You just provide a blood sample.
How long will my involvement last?
Your involvement is usually limited to one visit to provide a blood sample. There are no ongoing follow-up appointments for this study.
Who is funding this research?
The information provided does not specify the funding body for this particular study.
How to find out more
Lise Laclautre, PhD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.